Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir

Amit K. Verma, S. Devine, M. Morrow, Y. H. Chen, M. Mihalov, D. Peace, W. Stock, K. Pursell, A. Wickrema, M. Yassine, E. Jessop, K. van Besien

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day -2 and prophylactic acyclovir from day -1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31 ± 14% by day 100 and 35 ± 14% by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of high-dose acyclovir and possibly to pretransplant use of ganciclovir.

Original languageEnglish (US)
Pages (from-to)813-816
Number of pages4
JournalBone Marrow Transplantation
Volume31
Issue number9
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Ganciclovir
Acyclovir
Viremia
Transplants
Incidence
Stem Cell Transplantation
Tacrolimus
Methotrexate
Blood Cells
Transplantation
Steroids
Tissue Donors
Polymerase Chain Reaction

Keywords

  • Acyclovir
  • Allogeneic transplantation
  • CMV
  • Viremia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. / Verma, Amit K.; Devine, S.; Morrow, M.; Chen, Y. H.; Mihalov, M.; Peace, D.; Stock, W.; Pursell, K.; Wickrema, A.; Yassine, M.; Jessop, E.; van Besien, K.

In: Bone Marrow Transplantation, Vol. 31, No. 9, 05.2003, p. 813-816.

Research output: Contribution to journalArticle

Verma, AK, Devine, S, Morrow, M, Chen, YH, Mihalov, M, Peace, D, Stock, W, Pursell, K, Wickrema, A, Yassine, M, Jessop, E & van Besien, K 2003, 'Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir', Bone Marrow Transplantation, vol. 31, no. 9, pp. 813-816. https://doi.org/10.1038/sj.bmt.1703916
Verma, Amit K. ; Devine, S. ; Morrow, M. ; Chen, Y. H. ; Mihalov, M. ; Peace, D. ; Stock, W. ; Pursell, K. ; Wickrema, A. ; Yassine, M. ; Jessop, E. ; van Besien, K. / Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. In: Bone Marrow Transplantation. 2003 ; Vol. 31, No. 9. pp. 813-816.
@article{5a988757a71d44d19e4512a66468b00b,
title = "Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir",
abstract = "To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day -2 and prophylactic acyclovir from day -1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31 ± 14{\%} by day 100 and 35 ± 14{\%} by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of high-dose acyclovir and possibly to pretransplant use of ganciclovir.",
keywords = "Acyclovir, Allogeneic transplantation, CMV, Viremia",
author = "Verma, {Amit K.} and S. Devine and M. Morrow and Chen, {Y. H.} and M. Mihalov and D. Peace and W. Stock and K. Pursell and A. Wickrema and M. Yassine and E. Jessop and {van Besien}, K.",
year = "2003",
month = "5",
doi = "10.1038/sj.bmt.1703916",
language = "English (US)",
volume = "31",
pages = "813--816",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir

AU - Verma, Amit K.

AU - Devine, S.

AU - Morrow, M.

AU - Chen, Y. H.

AU - Mihalov, M.

AU - Peace, D.

AU - Stock, W.

AU - Pursell, K.

AU - Wickrema, A.

AU - Yassine, M.

AU - Jessop, E.

AU - van Besien, K.

PY - 2003/5

Y1 - 2003/5

N2 - To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day -2 and prophylactic acyclovir from day -1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31 ± 14% by day 100 and 35 ± 14% by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of high-dose acyclovir and possibly to pretransplant use of ganciclovir.

AB - To establish the incidence of CMV viremia after allogeneic blood stem cell transplantation, we studied 51 consecutive allogeneic peripheral blood stem cell (PBSC) transplant recipients. A total of 12 recipients were at moderate risk for CMV disease and 39 were at high risk. Conditioning regimens varied, but GvHD prophylaxis consisted of tacrolimus and mini-methotrexate in all patients. All patients received prophylactic ganciclovir from admission until day -2 and prophylactic acyclovir from day -1 until day 180 after transplantation. CMV viremia was treated with ganciclovir. Using a PCR-based technique, the cumulative incidence of CMV viremia was 31 ± 14% by day 100 and 35 ± 14% by day 150. Donor type, CMV risk group, underlying disorder, conditioning regimen, GvHD, and steroid use were not associated with the risk for CMV viremia. No cases of CMV disease occurred. We hypothesize that the low rate of CMV viremia and the absence of CMV disease in this cohort of PBSCT transplant recipients, which contrasts with other reports, may be related to the prophylactic use of high-dose acyclovir and possibly to pretransplant use of ganciclovir.

KW - Acyclovir

KW - Allogeneic transplantation

KW - CMV

KW - Viremia

UR - http://www.scopus.com/inward/record.url?scp=12444335609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444335609&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703916

DO - 10.1038/sj.bmt.1703916

M3 - Article

C2 - 12732890

AN - SCOPUS:12444335609

VL - 31

SP - 813

EP - 816

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -